(E)-3-(2-bromo-4,5-dimethoxyphenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one | 74753-40-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(2-bromo-4,5-dimethoxyphenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one
• 英文别名: 2-bromo-4,5,3',4'-tetramethoxychalcone；2-bromo-4,5,3',4'-tetramethoxy-trans-chalcone；2-Brom-4,5,3',4'-tetramethoxy-trans-chalkon
• CAS: 74753-40-5
• 化学式: C₁₉H₁₉BrO₅
• 分子量: 407.261
• InChiKey: WTIXPFFWZNLWMQ-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-(2-bromo-4,5-dimethoxyphenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one 在 三氟乙酸 作用下， 反应 24.0h， 以90%的产率得到3-(2-bromo-4,5-dimethoxyphenyl)-5,6-dimethoxyindan-1-one
  参考文献：
  名称：

  McDonald, Edward; Smith, Paul, Journal of the Chemical Society. Perkin transactions I, 1980, p. 837 - 842

  摘要：

  DOI：
• 作为产物：
  描述：

  6-溴藜芦醛 、 3,4-二甲氧基苯乙酮 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以56.3%的产率得到(E)-3-(2-bromo-4,5-dimethoxyphenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  찰콘 유도체를 포함하는 신장 보호용 조성물

  摘要：

  该规范涉及包含钙调素诱导体的肾脏保护配方或肾脏疾病改善配方，通过使用本规范中的化合物，可以保护肾脏免受药物等的肾毒性，从而促进与药物相关的肾脏疾病的有效改善，因此利用本规范可以在患者治疗和福利领域做出重大贡献。

  公开号：

  KR20190050074A

文献信息

• Compounds for the treatment of neurodegenerative diseases
  申请人：ProteoTech Inc.

  公开号：US20150011604A1

  公开（公告）日：2015-01-08

  Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

  化合物及其药用可接受的盐，用于治疗突触核蛋白病，例如帕金森病和tau蛋白病。
• Compounds for the treatment of Neurodegenerative Diseases
  申请人：PROTEOTECH INC

  公开号：US20150274681A1

  公开（公告）日：2015-10-01

  Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

  化合物及其药学上可接受的盐，用于治疗tau病变，例如阿尔茨海默病、皮克氏病、进行性上核性麻痹、皮质基底节变性、17号染色体关联的家族性额颞叶痴呆/帕金森综合征、肌萎缩侧索硬化/帕金森综合征-痴呆复合症、银染颗粒性痴呆、拳击性痴呆、伴有钙化的弥漫性神经纤维缠结、进行性皮层下胶质增生和仅有缠结的痴呆。
• 2-Bromo-4,5-Dimethoxy Chalcone Inhibits Cisplatin-induced LLC-PK1 Kidney Cell Death
  作者：Dahae Lee、Heesu Lee、Ki Sung Kang、Jae Wook Lee

  DOI：10.1002/bkcs.11454

  日期：2018.5

  The kidney has various functions, including modulating blood pressure, balancing electrolytes, and controlling blood volume. Among these functions, extracting metabolic waste from blood plays an important role in kidney. 1,2 Additionally, kidney epithelial cells are vulnerable to the toxic effects of various chemical agents and medications. 3,4 Recently, cisplatin, an inorganic platinum-based chemotherapeutic agent, has been used to inhibit solid malignant tumors due to its high therapeutic potential. 5,6 However, continuous exposure to cisplatin can cause various significant side effects, such as bone marrow suppression, peripheral neuropathy, and nephrotoxicity. In particular, a single dose of cisplatin treatment can cause nephrotoxicity among one-third of patients.(7-9) Therefore, it has been suggested to develop medication for cisplatin-induced nephrotoxicity.
• 282. Synthetical experiments in the chelidonine–sanguinarine group of the alkaloids. Part II
  作者：A. S. Bailey、Robert Robinson

  DOI：10.1039/jr9500001375

  日期：——
• MCDONALD E.; SMITH P., J. CHEM. SOC. PERKIN TRANS., PART 1, 1980, NO 4, 837-842
  作者：MCDONALD E.、 SMITH P.

  DOI：——

  日期：——